Business Context and Reporting Period
The filing is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020, although the request metadata identifies Spyre Therapeutics, Inc. Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapeutics and had no approved products or product revenue.
Key programs included pegzilarginase for Arginase 1 Deficiency, ACN00177 for Homocystinuria, and the AEB5100 program for Cystinuria.
Financial Performance and Position
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Research and development expense | $16.9 million, versus $14.8 million | $31.4 million, versus $29.2 million |
| General and administrative expense | $4.7 million, versus $3.8 million | $9.2 million, versus $7.1 million |
| Total operating expenses | $21.6 million, versus $18.6 million | $40.6 million, versus $36.3 million |
| Net loss | $21.4 million, versus $18.0 million | $40.1 million, versus $35.2 million |
| Net loss per share | $0.40, versus $0.55 | $0.93, versus $1.14 |
| Operating cash flow | Not separately provided | $(41.1) million, versus $(32.2) million |
- The company had no product revenue and reported an accumulated deficit of $235.3 million at June 30, 2020.
- Cash and cash equivalents were $65.7 million, marketable securities were $92.0 million, and restricted cash was $1.5 million. Total cash, cash equivalents, marketable securities, and restricted cash were $159.2 million.
- Working capital was approximately $146.0 million. Total assets were $172.9 million and total liabilities were $20.7 million.
- The company reported no debt or credit facility. Lease obligations totaled $8.9 million, including operating and finance leases.
- Financing activities generated $129.6 million during the first six months, primarily from the April 2020 public offering. Net cash increased by $46.5 million.
- Research and development spending increased primarily because of higher manufacturing and pre-commercial activities for pegzilarginase, increased Homocystinuria manufacturing activity, and higher personnel costs.
Material Changes Versus the Prior Comparable Period
- Six-month research and development expense rose 8% and general and administrative expense rose 29%, increasing total operating expenses by 12%.
- Six-month net loss increased 14%, while operating cash use increased by $8.9 million.
- Interest income declined 59% for the six-month period because of lower investment yields.
- In April 2020, Aeglea issued 15.4 million common shares and pre-funded warrants for up to 13.6 million additional shares, generating approximately $129.1 million of net proceeds. Total pre-funded warrants outstanding at June 30, 2020 were 17.6 million.
- Property and equipment purchases increased to $2.7 million from $0.2 million, while marketable securities increased substantially from year-end 2019.
Guidance, Outlook, Commentary, Risks and Unusual Items
- Management stated that existing cash, cash equivalents, and marketable securities were expected to fund operations through 2022, based on current plans. Additional financing will be required to complete all planned development activities.
- The company expected to continue incurring operating losses, with expenses increasing as it advanced clinical programs, prepared for potential commercialization, expanded its pipeline, and operated as a public company.
- Management expected to complete enrollment in the Phase 3 PEACE trial in the third quarter of 2020 and anticipated topline data in the first quarter of 2021.
- COVID-19 disrupted patient screening, dosing appointments, site operations, and recruitment. Management had not experienced a significant supply-chain impact at the filing date and stated that clinical supply was sufficient for ongoing trials, but future disruption remained uncertain.
- The ACN00177 Phase 1/2 trial had been initiated following United Kingdom regulatory approval, but timing of first patient dosing depended on individual clinical sites affected by COVID-19.
- The AEB5100 Cystinuria program continued with a concentrated internal effort because of COVID-19 impacts and prioritization of the pegzilarginase program.
- Reported pegzilarginase data included 13 patients, all achieving plasma arginine levels below 200 micromolar and 11 identified as clinical responders. Hypersensitivity and hyperammonemia were described as infrequent, expected, and manageable serious adverse events.
- Principal risks included clinical-trial failure or delay, regulatory non-approval, patient enrollment constraints, manufacturing and third-party dependence, adverse events, intellectual-property challenges, competition, future financing needs and dilution, reimbursement uncertainty, and COVID-19-related disruptions.
- The company had license obligations to the University of Texas at Austin, including potential development and regulatory milestone payments of up to $6.4 million, royalties on net sales, and revenue sharing on certain sublicense consideration.
- Disclosure controls and procedures were considered effective at the reasonable assurance level, and management reported no material changes in internal control over financial reporting during the quarter.
- Effective August 5, 2020, Suzanne Bruhn, Ph.D., resigned from the board and its committees; the filing stated that no disagreement caused the resignation.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Aeglea BioTherapeutics, Inc. (ticker AGLE), not Spyre Therapeutics, Inc.
- Verify the company’s cash runway assumptions and whether subsequent clinical, manufacturing, regulatory, or COVID-19 developments changed the stated ability to fund operations through 2022.
- Track PEACE Phase 3 enrollment, topline results, regulatory interactions, and any effect of missed dosing or screening delays.
- Assess dilution from the 17.6 million pre-funded warrants, the April 2020 equity offering, and the $60.0 million at-the-market facility.
- Review future financing requirements because the company had no product revenue, remained loss-making, and stated that additional funding would be needed.
- Evaluate the status of ACN00177, AEB5100, manufacturing capacity, third-party suppliers, and University of Texas license obligations.